Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | PNMT | P11086 | 1/20 | 0.46 |
| ▸ | IDO1 | P14902 | 3/20 | 0.43 |
| ▸ | TSHR | P16473 | 1/20 | 0.38 |
| ▸ | TAAR1 | Q96RJ0 | 3/20 | 0.36 |
| ▸ | TP53 | P04637 | 1/20 | 0.36 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.36 |
| ▸ | CSNK2B | P67870 | 1/20 | 0.36 |
| ▸ | CSNK2A1 | P68400 | 1/20 | 0.36 |
| ▸ | MAOB | P27338 | 3/20 | 0.35 |
| ▸ | CCR5 | P51681 | 1/20 | 0.35 |
| ▸ | LOX | P28300 | 1/20 | 0.34 |
| ▸ | LOXL3 | P58215 | 1/20 | 0.34 |
| ▸ | LOXL2 | Q9Y4K0 | 1/20 | 0.34 |
| ▸ | HTR3E | A5X5Y0 | 1/20 | 0.33 |
| ▸ | HTR3B | O95264 | 1/20 | 0.33 |
| ▸ | HTR3A | P46098 | 1/20 | 0.33 |
| ▸ | HTR3D | Q70Z44 | 1/20 | 0.33 |
| ▸ | HTR3C | Q8WXA8 | 1/20 | 0.33 |
| ▸ | NOTUM | Q6P988 | 1/20 | 0.32 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29897365 | 1.00 | PNMT (0.46) | PNMTIDO1TSHRTAAR1TP53 | |
| SCHEMBL111874 | 0.87 | PNMT (0.56) | PNMTIDO1TSHRTAAR1TP53 | |
| SCHEMBL1765119 | 0.84 | IDO1 (0.52) | PNMTIDO1TAAR1LOXL2 | |
| SCHEMBL625883 | 0.82 | PNMT (0.56) | PNMTIDO1TSHRTAAR1TP53 | |
| SCHEMBL1872002 | 0.82 | IDO1 (0.50) | PNMTIDO1TAAR1LOXL2 | |
| 1,3,5-Trichlorobenzene SCHEMBL865477 | 0.79 | TSHR (0.61) | IDO1TSHRTP53CYP3A4HTR3E | |
| SCHEMBL151031 | 0.79 | — | — | |
| SCHEMBL114694 | 0.79 | — | — | |
| SCHEMBL28894230 | 0.78 | TSHR (0.40) | IDO1TSHRTP53CYP3A4HTR3E | |
| SCHEMBL29999249 | 0.78 | TSHR (0.40) | IDO1TSHRTP53CYP3A4HTR3E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 68 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | CANCER RESEARCH TECHNOLOGY LIMITED (GB) | 2026-05-26 | — | — | US | disclosed |
| EP-4567035-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | Nextgen Bioscience Co., Ltd. (KR) | 2025-06-11 | — | — | EP | disclosed |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | HOFFMANN-LA ROCHE INC. (US) | 2025-02-20 | — | — | US | disclosed |
| US-12195490-B2 | STRAD-binding agents and uses thereof | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-01-14 | — | — | US | disclosed |
| EP-4448522-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. Hoffmann-La Roche AG (CH) | 2024-10-23 | — | — | EP | disclosed |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | INSTITUT PASTEUR DE LILLE (FR) | 2024-10-03 | — | — | US | disclosed |
| WO-2024130095-A9 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-08-02 | — | — | WO | disclosed |
| WO-2024130095-A1 | COMPOUNDS AND COMPOSITIONS AS CBP/P300 DEGRADERS AND USES THEREOF | REGENTS OF THE UNIVERSITY OF MICHIGAN (US) | 2024-06-20 | — | — | WO | disclosed |
| WO-2024030000-A1 | NOVEL COMPOUND AS HYPOXIA-INDUCIBLE FACTOR 1(HIF-1) INHIBITOR OR VASCULAR ENDOTHELIAL GROWTH FACTOR (VEGF) INHIBITOR, AND PHARMACEUTICAL COMPOSITION COMPRISING SAME | 주식회사 넥스트젠바이오사이언스 | 2024-02-08 | — | — | WO | disclosed |
| WO-2023110958-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | F. HOFFMANN-LA ROCHE AG (CH) | 2023-06-22 | — | — | WO | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-7273882-B2 | Aminoacetamide acyl guanidines as β-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-09-25 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2007-01-18 | — | — | US | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002214-A2 | ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| WO-2007002220-A2 | AMINOACETAMIDE ACYL GUANIDINES AS BETA-SECRETASE INHIBITORS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2007-01-04 | — | — | WO | disclosed |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | BRISTOL-MYERS SQUIBB COMPANY | 2006-12-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-12637428-B2 | Isoquinoline derivatives as SIK2 inhibitors | SIK2, SIK1, SIK3 | PNMT 1956/4885IDO1 325/4885TSHR 985/4885 |
| US-20240327354-A1 | GRAM-NEGATIVE BACTERIA EFFLUX PUMP INHIBITORS | ABCB11, ABCB1, ATP4B | PNMT 875/4885IDO1 2360/4885TSHR 4580/4885 |
| US-20250059185-A1 | BICYCLIC HETEROCYCLIC COMPOUNDS USEFUL AS MONOACYLGLYCEROL LIPASE INHIBITORS | MGLL, LIPC, PNLIP | PNMT 3404/4885IDO1 2862/4885TSHR 3993/4885 |
| US-20060287287-A1 | Aminoacetamide acyl guanidines as beta-secretase inhibitors | APP, BACE1, BACE2 | PNMT 488/4885IDO1 2441/4885TSHR 4211/4885 |
| US-20070015754-A1 | Acyl guanidines as beta-secretase inhibitors | BACE1, APP, BACE2 | PNMT 872/4885IDO1 3885/4885TSHR 3913/4885 |
| US-12195490-B2 | STRAD-binding agents and uses thereof | STRAP, STRA6, PLAUR | PNMT 3704/4885IDO1 4177/4885TSHR 1833/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.